Sheets Smith Wealth Management’s Virpax Pharmaceuticals, Inc. Common Stock VRPX Stock Holding History

Sheets Smith Wealth Management’s Portfolio VRPX Stock Details VRPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-200	Closed	-$16K	–	395
2023 Q4	$16K	Buy	+200	New	+$30K	﹤0.01%	350

Other funds holding VRPX

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

SRCM

Signature Resources Capital Management Newport Beach, California $254M AUM 26.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Sheets Smith Wealth Management's VRPX Position: Q1 2024 in Review

Sheets Smith Wealth Management sold out of Virpax Pharmaceuticals, Inc. Common Stock (VRPX) in Q1 2024, closing a stake of 200 shares — an estimated $16K sold.

Sheets Smith Wealth Management first reported a position in VRPX in Q4 2023 and held it in 1 quarter. The position peaked at $16K in Q4 2023. 3 funds tracked by Wall St. Rank hold VRPX as of Q1 2024.

Sheets Smith Wealth Management reported no remaining Virpax Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Sheets Smith Wealth Management sold 200 Virpax Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $16K.
Sheets Smith Wealth Management first reported a position in Virpax Pharmaceuticals, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
Sheets Smith Wealth Management's Virpax Pharmaceuticals, Inc. Common Stock position peaked at $16K in Q4 2023.
3 funds tracked by Wall St. Rank held Virpax Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Sheets Smith Wealth Management's 13F filing for Q1 2024, filed 8 May 2024.